GlobeNewswire by notified

Fujifilm Europe supports World Cancer Day

Share

RATINGEN, Germany, Jan. 23, 2023 (GLOBE NEWSWIRE) -- Fujifilm Europe has announced its partnership with World Cancer Day, an initiative led by the Union for International Cancer Control (UICC), the largest and oldest international cancer organisation dedicated to taking the lead in convening, capacity building and advocacy initiatives that unite the cancer community to reduce the global cancer burden, promote greater equity, and integrate cancer control into the world health and development agenda.

The day takes place on the 4th of February each year, and aims to raise awareness and improve education about cancer, as well as encourage governments to take action against the disease.

This year’s theme is ‘closing the care gap’, and focuses on the lack of accessibility to health services faced by many people around the world. Half the world’s population lacks access to the full range of essential health services. When it comes to cancer, many people are denied basic care, despite the fact that we live in a time of awe-inspiring advancements in cancer prevention, diagnosis and treatment.

Fujifilm is committed to achieving universal health coverage, ensuring that everyone can access essential medical services. This extends not only to regions with less developed medical infrastructures, but also to advanced countries. To this end, Fujifilm’s devices have long supported healthcare professionals in making prompt and accurate diagnoses. The company continually develops novel devices, upgrades its technologies and harnesses advanced AI algorithms to make screening more accessible around the world.

These solutions extend to cancer prevention, screening and diagnosis, where they help to identify diseases at an early stage. Toshihisa Iida, President and Managing Director at FUJIFILM Europe GmbH, commented: “We are extremely proud to be a partner of World Cancer Day, and to show our dedication to advancing the fight against cancer. We believe access to medical care should be equal for all, and this can only be achieved by removing the geographical and economic barriers that block the latest innovations from reaching many patients. Although this is a difficult task, there is progress, and we will continue to support initiatives like this to work towards our vision for a healthier world.”

Dr Cary Adams, CEO of the Union for International Cancer Control
“As individuals, as communities, we can and must come together and break down barriers. We have achieved a lot in the last decade in cancer care and control around the world but not addressing inequities in society is slowing our progress. Closing the care gap is about fairness, dignity and fundamental rights to allow everyone to lead longer lives in better health.”

Read more about Fujifilm here fujifilm.com/uk/en/neverstop/worldcancerday

About FUJIFILM Europe GmbH

Fujifilm operates over 50 group companies and branches in Europe and employs more than 6000 people engaged in R&D, manufacturing, sales and service, with FUJIFILM Europe GmbH, located in Ratingen, Germany, operating as the strategic headquarters for the region. Throughout Europe, Fujifilm entities serve a range of industries including medical technology, biopharmaceuticals, electronic materials, industrial products, chemicals, graphic systems, optical devices, data storage and all aspects of photography. Over the last 20 years, the company has more intensively focused on healthcare - from diagnosis to prevention and treatment. Today, Fujifilm in Europe provides the entire spectrum of patient care, in addition to research, development and CDMO manufacturing in advanced therapies, gene therapies and vaccines, as well as providing cell culture media and regenerative medicine solutions.
For more information, please visit: fujifilm.com

About World Cancer Day
World Cancer Day on 4 February is a uniting global initiative spearheaded by the Union for International Cancer Control (UICC) to raise awareness and improve education about the disease, while calling for action from governments and individuals across the world.

Luana Porfido
Head of Corporate Communications - Europe
FUJIFILM Europe GmbH
luana.porfido@fujifilm.com
+39 (0)3459529101

Andy Ross
Deputy Head of Corporate Communications - Europe
FUJIFILM Europe GmbH
andy.jm.ross@fujifilm.com
+44 (0)7766497949

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/a3984b37-4f77-487b-a13d-89d77cd06530

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

AKVA group ASA: Q1 2024 financial reporting3.5.2024 07:59:43 CEST | Press release

Acceptable activity level in Sea Based and improved profitability. AKVA group delivered revenue for Q1 2024 of MNOK 784 (874), a decrease of 10% compared to Q1 2023. EBITDA increased from MNOK 59 in Q1 2023 to MNOK 67 in Q1 2024. Total order intake of MNOK 917 (1,170) in Q1 2024 supported by strong order intake of MNOK 800 in Sea Based. Order backlog of BNOK 2,6 at the end of March 2024. Award of three new barges for the Nordic market with a total contract value of approx. MNOK 160. The activity level in Sea Based was acceptable in the first quarter of 2024 with a strong order intake of MNOK 800. The high order intake was driven by the award of three new barges for the Nordic market. The market for Land Based is still slow and AKVA does not expect to sign any new significant contracts during the first half of 2024. The outlook for the post smolt market in Norway is still challenging due to the resource tax but is expected to normalize during the second half of 2024. Profitability impro

Q1 update: Novonesis delivers 4% organic sales growth in line with expectations and reports progress on the integration3.5.2024 07:57:38 CEST | Press release

For the first quarter as Novonesis, the company delivers 4% organic sales growth in line with expectations. Novonesis maintains the 2024 outlook of 5-7% organic sales growth with an adjusted EBITDA margin of around 35%. COPENHAGEN, Denmark – May 3, 2024. In the first three months of the 2024 financial year, Novonesis delivers 4% organic sales growth against a strong comparator. The organic sales growth in the first quarter is driven by both Food & Health Biosolutions and Planetary Health Biosolutions. Overall, volumes increased by around 2% and pricing contributed around 2%. “We are off to a good start. With 4% organic sales growth, we deliver in line with expectations for the first three months, and we continue to successfully move forward on the integration. Being in a place of comfort, we are already seeing synergies from bringing the two great legacy companies together, and we are fully focused on both short and long-term deliverables and developments. I am proud and thankful to se

Trading statement Q1 20243.5.2024 07:56:10 CEST | Press release

Novonesis realized 4% organic sales growth in line with expectations and maintains 2024 outlook. Ester Baiget, President & CEO: “I am pleased with the first quarter organic sales growth of 4% with growth in both Food & Health and Planetary Health. We are off to a good start in line with expectations and very well on track to deliver 5-7% organic sales growth for the full year with an adjusted EBITDA margin of around 35%. It’s highly comforting to see our new organization’s focus on both short and long-term deliverables and developments.” Pro forma sales performance¹ (organic sales growth calculation capped for hyperinflation countries) Against a strong comparable Novonesis realized 4% pro forma organic sales growth in Q1 2024. Volumes increased by around 2% and pricing also contributed around 2%. Pro forma sales in EUR amounted to 965.5 million, an increase of 1% (organic +4%, currency -2%, M&A -1%). Emerging markets grew 14% organically, while developed markets declined 1%. Food & Hea

Netcompany - Launch of share buyback programme3.5.2024 07:31:47 CEST | Press release

Company announcement No. 19/2024 3 May 2024 Launch of share buyback programme Today, Netcompany Group A/S (“Netcompany”) announces that the Board of Directors has decided to initiate a share buyback programme of up to DKK 250m for the purpose of meeting the future commitments under its LTIP programmes (RSU). The share buyback programme is launched with reference to the authorisation to acquire treasury shares granted by the general meeting on 2 March 2023. The authorisation is valid until 2 March 2028 and allows Netcompany to acquire shares with a total nominal value of up to 10% of its share capital. The share buyback programme will end no later than 12 August 2024. The share buyback programme will be executed in accordance with EU Market Abuse Regulation, EU Regulation no. 596/2014 of 16 April 2014 and the provisions of Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the “Safe Harbour Regulation”). Netcompany has appointed Nordea Danmark, Filial af Nordea Bank Abp, Fi

Selskabsmeddelelse – 1. kvartal 20243.5.2024 07:31:00 CEST | pressemeddelelse

Selskabsmeddelelse – 1. kvartal 2024 Administrerende direktør Kamilla Hammerich Skytte udtaler om 1. kvartal 2024: “Realkredit Danmark opnåede et stabilt resultat i 1. kvartal 2024 på 1.005 mio. kr. Den positive udvikling i toplinjen skyldtes det højere renteniveau. Periodens resultat faldt med 58 mio. kr. som følge af øgede modelbaserede nedskrivninger på udlån. Aktiviteten på boligmarkedet var som ventet lav i starten af året som følge af boligskattereformen, der betød, at en del bolighandler var blevet fremskyndet til slutningen af 2023. Der var dog en stigning i antallet af bolighandler hen mod slutningen af kvartalet. Forventningen til 2024 er, at vi generelt kommer til at se moderate stigninger i boligpriserne på landsplan. Pæne lønstigninger, og dermed en genvunden købekraft, vil sammen med lav ledighed og udsigt til fornuftig økonomisk aktivitet i samfundet have en positiv afsmitning på boligmarkedet. Omvendt er renteniveauet væsentligt højere end for få år siden, ligesom købek

HiddenA line styled icon from Orion Icon Library.Eye